Table 3 Factors potentially associated with an increased risk of molecular relapse after discontinuation of TKI treatment in CML
Covariate | No. patients per group | Subhazard ratio (95% CI) | P-value |
|---|---|---|---|
Sex (male vs. female) | 113 / 123 | 1.05 (0.64–1.71) | 0.83 |
Age (> 60 vs. ≤ 60 years) | 125 / 111 | 1.03 (0.63–1.69) | 0.87 |
Sokal risk index (high vs. low-intermediate) | 17 / 198 | 1.54 (0.73–3.25) | 0.25 |
BCR-ABL transcript type (e13a2 vs. e14a2) | 70 / 104 | 0.78 (0.43–1.42) | 0.43 |
History of TKI resistance (yes vs. no) | 17 / 219 | 1.14 (0.43–3.06) | 0.28 |
No. of TKI lines before discontinuation (> 1 vs. 1) | 52 / 184 | 1.21 (0.67–2.2) | 0.51 |
TKI at the time of discontinuation (imatinib vs. others) | 175 / 61 | 0.77 (0.44–1.33) | 0.35 |
Prior exposure to interferon (yes vs. no) | 55 / 181 | 0.53 (0.28–1.01) | 0.055 |
Duration of TKI treatment (< 5 years vs. ≥ 5 years) | 19 /217 | 2.59 (1.33–5.01) | 0.005 |
Time in MR4.5 before discontinuation (< 4 years vs. ≥ 4 years) | 82 / 153 | 2.06 (1.27–3.35) | 0.003 |
